NO313103B1 - Fremgangsmåte for screening for proteininhibitorer og aktiveringsmidler, samt testceller og testkit - Google Patents

Fremgangsmåte for screening for proteininhibitorer og aktiveringsmidler, samt testceller og testkit Download PDF

Info

Publication number: NO313103B1
Authority: NO; Norway
Prior art keywords: cell; protein; response; phenotypic; compound
Prior art date: 1988-02-10

Application number

NO19903494A

Other languages

English (en)

Norwegian (no)

Other versions

NO903494L (no

NO903494D0 (no

Inventor

Gerard M Housey

Original Assignee

Housey Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-02-10

Filing date

1990-08-08

Publication date

2002-08-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22550430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO313103(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-08-08 Application filed by Housey Pharmaceuticals Inc filed Critical Housey Pharmaceuticals Inc

1990-08-08 Publication of NO903494D0 publication Critical patent/NO903494D0/no

1990-10-01 Publication of NO903494L publication Critical patent/NO903494L/no

2002-08-12 Publication of NO313103B1 publication Critical patent/NO313103B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 96
239000012190 activator Substances 0.000 title claims abstract description 35
238000012360 testing method Methods 0.000 title claims description 47
238000012216 screening Methods 0.000 title description 18
238000003149 assay kit Methods 0.000 title description 2
229940121649 protein inhibitor Drugs 0.000 title description 2
239000012268 protein inhibitor Substances 0.000 title description 2
108090000623 proteins and genes Proteins 0.000 claims abstract description 191
102000004169 proteins and genes Human genes 0.000 claims abstract description 143
230000008859 change Effects 0.000 claims abstract description 43
239000003112 inhibitor Substances 0.000 claims abstract description 38
229920001817 Agar Polymers 0.000 claims abstract description 37
239000008272 agar Substances 0.000 claims abstract description 37
230000009120 phenotypic response Effects 0.000 claims abstract description 20
238000004113 cell culture Methods 0.000 claims abstract description 4
210000004027 cell Anatomy 0.000 claims description 397
108090000315 Protein Kinase C Proteins 0.000 claims description 112
102000003923 Protein Kinase C Human genes 0.000 claims description 110
150000001875 compounds Chemical class 0.000 claims description 60
230000012010 growth Effects 0.000 claims description 58
230000000694 effects Effects 0.000 claims description 40
230000004044 response Effects 0.000 claims description 28
239000013598 vector Substances 0.000 claims description 24
230000014509 gene expression Effects 0.000 claims description 17
238000004519 manufacturing process Methods 0.000 claims description 15
102000004190 Enzymes Human genes 0.000 claims description 14
108090000790 Enzymes Proteins 0.000 claims description 14
210000002950 fibroblast Anatomy 0.000 claims description 14
230000000877 morphologic effect Effects 0.000 claims description 12
239000012634 fragment Substances 0.000 claims description 9
108700020796 Oncogene Proteins 0.000 claims description 8
230000036755 cellular response Effects 0.000 claims description 7
230000004913 activation Effects 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 6
230000001965 increasing effect Effects 0.000 claims description 6
230000005764 inhibitory process Effects 0.000 claims description 6
208000005623 Carcinogenesis Diseases 0.000 claims description 5
230000036952 cancer formation Effects 0.000 claims description 5
231100000504 carcinogenesis Toxicity 0.000 claims description 5
230000001419 dependent effect Effects 0.000 claims description 5
230000002068 genetic effect Effects 0.000 claims description 5
230000001177 retroviral effect Effects 0.000 claims description 5
108700005126 Ornithine decarboxylases Proteins 0.000 claims description 4
102000052812 Ornithine decarboxylases Human genes 0.000 claims description 4
230000004071 biological effect Effects 0.000 claims description 4
230000004069 differentiation Effects 0.000 claims description 3
230000001747 exhibiting effect Effects 0.000 claims description 2
238000003780 insertion Methods 0.000 claims description 2
230000037431 insertion Effects 0.000 claims description 2
230000000890 antigenic effect Effects 0.000 claims 2
108091028043 Nucleic acid sequence Proteins 0.000 claims 1
230000002596 correlated effect Effects 0.000 claims 1
238000010899 nucleation Methods 0.000 claims 1
150000007523 nucleic acids Chemical group 0.000 claims 1
210000001768 subcellular fraction Anatomy 0.000 claims 1
239000000126 substance Substances 0.000 abstract 4
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 46
239000002299 complementary DNA Substances 0.000 description 37
239000013612 plasmid Substances 0.000 description 24
239000003795 chemical substances by application Substances 0.000 description 20
239000002609 medium Substances 0.000 description 16
230000010261 cell growth Effects 0.000 description 15
238000003556 assay Methods 0.000 description 14
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 12
239000013604 expression vector Substances 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 11
108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
101000669508 Mus musculus Metalloproteinase inhibitor 1 Proteins 0.000 description 10
239000000284 extract Substances 0.000 description 10
230000027455 binding Effects 0.000 description 9
239000001963 growth medium Substances 0.000 description 9
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 9
239000002644 phorbol ester Substances 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 8
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 8
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
230000035578 autophosphorylation Effects 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
239000000758 substrate Substances 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000003550 marker Substances 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
238000010367 cloning Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
241000700605 Viruses Species 0.000 description 5
150000001413 amino acids Chemical group 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000010276 construction Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000002955 isolation Methods 0.000 description 5
108020004999 messenger RNA Proteins 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
238000012546 transfer Methods 0.000 description 5
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 4
102100029974 GTPase HRas Human genes 0.000 description 4
101710091881 GTPase HRas Proteins 0.000 description 4
241000713869 Moloney murine leukemia virus Species 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
239000011539 homogenization buffer Substances 0.000 description 4
238000004264 monolayer culture Methods 0.000 description 4
238000012261 overproduction Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000523 sample Substances 0.000 description 4
229960001603 tamoxifen Drugs 0.000 description 4
239000000717 tumor promoter Substances 0.000 description 4
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
102100030013 Endoribonuclease Human genes 0.000 description 3
101710199605 Endoribonuclease Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
229920003091 Methocel™ Polymers 0.000 description 3
241000276498 Pollachius virens Species 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 3
108020004440 Thymidine kinase Proteins 0.000 description 3
239000013543 active substance Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000011575 calcium Substances 0.000 description 3
244000309466 calf Species 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
238000007877 drug screening Methods 0.000 description 3
239000012737 fresh medium Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004660 morphological change Effects 0.000 description 3
230000035772 mutation Effects 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
108091005981 phosphorylated proteins Proteins 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000002356 single layer Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
238000001890 transfection Methods 0.000 description 3
VXDQXODPWYRILN-UHFFFAOYSA-N 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-1h-tetrazol-1-ium;chloride;hydrate Chemical compound O.[Cl-].C1=CC([N+](=O)[O-])=CC=C1N1N(C=2C=CC(I)=CC=2)[NH+]=C(C=2C=CC=CC=2)N1 VXDQXODPWYRILN-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
102000001301 EGF receptor Human genes 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
108010033040 Histones Proteins 0.000 description 2
101710154356 Hypoxanthine/guanine phosphoribosyltransferase Proteins 0.000 description 2
102000003746 Insulin Receptor Human genes 0.000 description 2
108010001127 Insulin Receptor Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
101710160107 Outer membrane protein A Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108020004566 Transfer RNA Proteins 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
238000002802 antimicrobial activity assay Methods 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
239000013043 chemical agent Substances 0.000 description 2
230000001086 cytosolic effect Effects 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
102000027411 intracellular receptors Human genes 0.000 description 2
108091008582 intracellular receptors Proteins 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
102000016914 ras Proteins Human genes 0.000 description 2
108010014186 ras Proteins Proteins 0.000 description 2
238000012552 review Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000012289 standard assay Methods 0.000 description 2
238000012549 training Methods 0.000 description 2
230000009466 transformation Effects 0.000 description 2
231100000588 tumorigenic Toxicity 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
210000003934 vacuole Anatomy 0.000 description 2
QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
108700020911 DNA-Binding Proteins Proteins 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241001452028 Escherichia coli DH1 Species 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 1
102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
108700005084 Multigene Family Proteins 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
102000003505 Myosin Human genes 0.000 description 1
108060008487 Myosin Proteins 0.000 description 1
241001045988 Neogene Species 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
241001505332 Polyomavirus sp. Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102100040120 Prominin-1 Human genes 0.000 description 1
102000012515 Protein kinase domains Human genes 0.000 description 1
108050002122 Protein kinase domains Proteins 0.000 description 1
108020005067 RNA Splice Sites Proteins 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
102000044126 RNA-Binding Proteins Human genes 0.000 description 1
108700020471 RNA-Binding Proteins Proteins 0.000 description 1
229940078123 Ras inhibitor Drugs 0.000 description 1
102000001332 SRC Human genes 0.000 description 1
108060006706 SRC Proteins 0.000 description 1
101000717877 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S11-A Proteins 0.000 description 1
101000717881 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S11-B Proteins 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000002001 anti-metastasis Effects 0.000 description 1
230000002622 anti-tumorigenesis Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
RHJPBGWFGOAEID-UHFFFAOYSA-N aplysiatoxin Natural products O1C2(OC(O)(CC(=O)OC(CC(=O)O3)C(C)O)C(C)CC2(C)C)CC3C(C)C1C(C)CCC(OC)C1=CC(O)=CC=C1Br RHJPBGWFGOAEID-UHFFFAOYSA-N 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000005889 cellular cytotoxicity Effects 0.000 description 1
RHJPBGWFGOAEID-BEDNPZBZSA-N chembl1256416 Chemical compound C1([C@H](CC[C@H](C)[C@@H]2[C@H]([C@@H]3C[C@@]4(O[C@@](O)(CC(=O)O[C@H](CC(=O)O3)[C@@H](C)O)[C@H](C)CC4(C)C)O2)C)OC)=CC(O)=CC=C1Br RHJPBGWFGOAEID-BEDNPZBZSA-N 0.000 description 1
239000013000 chemical inhibitor Substances 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
238000010293 colony formation assay Methods 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000010410 layer Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000006241 metabolic reaction Methods 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
DLEDLHFNQDHEOJ-UDTOXTEMSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)[C@@]4(CO)O[C@H]4[C@H]3[C@H]3O[C@@](O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-UDTOXTEMSA-N 0.000 description 1
DLEDLHFNQDHEOJ-KVZAMRGJSA-N mezerein Natural products CC1C(OC(=O)C=C/C=C/c2ccccc2)C3(OC4(OC3C5C6OC6(CO)C(O)C7(O)C(C=C(C)C7=O)C15O4)c8ccccc8)C(=C)C DLEDLHFNQDHEOJ-KVZAMRGJSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229940123638 p21 inhibitor Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
BQJRUJTZSGYBEZ-YVQNUNKESA-N phorbol 12,13-dibutanoate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(=O)CCC)C1(C)C BQJRUJTZSGYBEZ-YVQNUNKESA-N 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
238000007747 plating Methods 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000034918 positive regulation of cell growth Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000000722 protumoral effect Effects 0.000 description 1
239000013014 purified material Substances 0.000 description 1
108700042226 ras Genes Proteins 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000004895 subcellular structure Anatomy 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
PEYTUVXFLCCGCC-YGHSORLUSA-N teleocidin b Chemical compound C1[C@@H](CO)NC(=O)[C@H](C(C)C)N(C)C2=CC([C@@](CC[C@]3(C)C=C)(C)C(C)C)=C3C3=C2C1=CN3 PEYTUVXFLCCGCC-YGHSORLUSA-N 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
- G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
General Engineering & Computer Science (AREA)
Physiology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19903494A 1988-02-10 1990-08-08 Fremgangsmåte for screening for proteininhibitorer og aktiveringsmidler, samt testceller og testkit NO313103B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/154,206 US4980281A (en)	1988-02-10	1988-02-10	Method of screening for protein inhibitors and activators
PCT/US1989/000462 WO1989007654A1 (en)	1988-02-10	1989-02-09	Method of screening for protein inhibitors and activators

Publications (3)

Publication Number	Publication Date
NO903494D0 NO903494D0 (no)	1990-08-08
NO903494L NO903494L (no)	1990-10-01
NO313103B1 true NO313103B1 (no)	2002-08-12

Family

ID=22550430

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19903494A NO313103B1 (no)	1988-02-10	1990-08-08	Fremgangsmåte for screening for proteininhibitorer og aktiveringsmidler, samt testceller og testkit
NO20021142A NO20021142D0 (no)	1988-02-10	2002-03-07	Fremgangsmåte for fremstilling av en aktivator eller inhibitorforbindelse

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20021142A NO20021142D0 (no)	1988-02-10	2002-03-07	Fremgangsmåte for fremstilling av en aktivator eller inhibitorforbindelse

Country Status (18)

Country	Link
US (1)	US4980281A (de)
EP (1)	EP0403506B1 (de)
JP (1)	JPH03503598A (de)
AT (1)	ATE140267T1 (de)
AU (1)	AU612948B2 (de)
BG (1)	BG60325B2 (de)
CA (1)	CA1334927C (de)
DE (1)	DE68926816T2 (de)
DK (2)	DK189590A (de)
ES (1)	ES2010131A6 (de)
FI (1)	FI102618B1 (de)
HU (1)	HU208555B (de)
IE (1)	IE77332B1 (de)
IL (1)	IL89227A (de)
MX (1)	MX165993B (de)
NO (2)	NO313103B1 (de)
RO (1)	RO118452B1 (de)
WO (1)	WO1989007654A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5688655A (en) *	1988-02-10	1997-11-18	Ict Pharmaceuticals, Inc.	Method of screening for protein inhibitors and activators
US5266464A (en) *	1988-02-10	1993-11-30	Ict Pharmaceuticals, Inc.	Method of screening for protein inhibitors and activators
EP0528827B1 (de) *	1990-04-19	1996-09-04	The General Hospital Corporation	Screening nach proteinpartnern und deren verwendung
US5322801A (en) *	1990-04-19	1994-06-21	The General Hospital Corporation	Protein partner screening assays and uses thereof
US6080540A (en) *	1990-04-20	2000-06-27	Cold Spring Harbor Laboratory	Cloning of mammalian genes in microbial organisms and methods for pharmacological screening
FI931268L (fi) *	1990-09-24	1993-04-21	Gen Hospital Corp	Saollningsfoerfaranden
US5707810A (en) *	1991-03-11	1998-01-13	Creative Biomolecules, Inc.	Method of diagnosing renal tissue damage or disease
US5650276A (en) *	1991-03-11	1997-07-22	Creative Biomolecules, Inc.	Morphogenic protein screening method
ATE250629T1 (de) *	1991-04-19	2003-10-15	Univ Washington	Für säugetierphosphodiesterasen kodierende dns
US5747341A (en) *	1991-06-24	1998-05-05	Pacific Biomedical Research, Inc.	Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
EP0605428B9 (de) *	1991-06-24	2003-01-02	hCell Technology, Inc.	In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
US5821121A (en) *	1991-06-24	1998-10-13	Pacific Biomedical Research, Inc.	Hormone-secreting cells maintained in long-term culture
WO1993002209A1 (en) *	1991-07-22	1993-02-04	The Regents Of The University Of California	Methods of designing specific affectors using three-dimensional conformation of enzyme/affector complex
AU696364B2 (en) *	1991-08-30	1998-09-10	Creative Biomolecules, Inc.	Morphogenic protein screening method II
EP0825442A3 (de) *	1991-08-30	2004-02-11	Curis, Inc.	Screeningverfahren von morphogenischen Proteinen
GB9216654D0 (en) *	1992-08-05	1992-09-16	Imp Cancer Res Tech	Transformed cells and assays using them
US6048850A (en) *	1992-09-22	2000-04-11	Young; Donald A.	Method of inhibiting prostaglandin synthesis in a human host
US5837479A (en) *	1992-09-22	1998-11-17	Young; Donald A.	Screening assays for inhibitors of mammalian prostaglandin H synthase-2
DE4306547C2 (de) *	1993-03-03	1996-07-11	Gsf Forschungszentrum Umwelt	In-vitro-Test zur Detektion von Proteinkinase C Inhibitoren
JPH09501302A (ja) *	1993-04-07	1997-02-10	キャンサーリサーチキャンペーンテクノロジーリミティド	治療活性についての物質のスクリーニングのための方法及びそれにおいて利用するための方法
US5776685A (en) *	1993-07-19	1998-07-07	Joslin Diabetes Center	Protein kinase C assay
JPH09510104A (ja) *	1994-03-10	1997-10-14	ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク	形質転換の進行の誘導性阻害剤を同定する方法
DE69532127T2 (de)	1994-07-20	2004-08-26	Genetics Institute, Inc., Cambridge	Interaktions-fullensysteme zum nachweis von protein-interaktionen
US6399296B1 (en) *	1994-07-20	2002-06-04	The General Hospital Corporation	Interaction trap systems for detecting protein interactions
US5597697A (en) *	1994-09-30	1997-01-28	Diamond; Paul	Screening assay for inhibitors and activators of RNA and DNA-dependent nucleic acid polymerases
KR100402836B1 (ko) *	1995-05-11	2004-02-19	주식회사 엘지생명과학	단백질간의상호작용을조절하는물질의새로운탐색시스템
US6365344B1 (en) *	1996-01-23	2002-04-02	The Board Of Trustees Of The Leland Stanford Junior University	Methods for screening for transdominant effector peptides and RNA molecules
DK0877752T3 (da)	1996-01-23	2003-09-15	Univ Leland Stanford Junior	Fremgangsmåder til screening af transdominante effektorpeptider og RNA molekyler
US5928888A (en) *	1996-09-26	1999-07-27	Aurora Biosciences Corporation	Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
AU724107B2 (en) *	1997-01-31	2000-09-14	Fred Hutchinson Cancer Research Center	Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin E
US7507705B2 (en)	1997-10-02	2009-03-24	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
WO1999024563A1 (en)	1997-11-07	1999-05-20	Iconix Pharmaceuticals, Inc.	Surrogate genetics target characterization method
PL340433A1 (en)	1997-11-10	2001-02-12	Gen Hospital Corp	Detection systems for detecting and recording protein-specific actions and functional interactions
US6362009B1 (en)	1997-11-21	2002-03-26	Merck & Co., Inc.	Solid phase synthesis of heterocycles
US6811992B1 (en) *	1998-05-14	2004-11-02	Ya Fang Liu	Method for identifying MLK inhibitors for the treatment of neurological conditions
US6518035B1 (en)	1998-06-02	2003-02-11	Rosetta Inpharmatics, Inc.	Targeted methods of drug screening using co-culture methods
US6720139B1 (en)	1999-01-27	2004-04-13	Elitra Pharmaceuticals, Inc.	Genes identified as required for proliferation in Escherichia coli
US6589738B1 (en)	1999-11-09	2003-07-08	Elitra Pharmaceuticals, Inc.	Genes essential for microbial proliferation and antisense thereto
US6689558B2 (en)	2000-02-08	2004-02-10	Sangamo Biosciences, Inc.	Cells for drug discovery
AU2001289284A1 (en) *	2000-04-04	2001-10-15	Enanta Pharmaceuticals, Inc.	Methods for identifying peptide aptamers capable of altering a cell phenotype
CA2408743A1 (en) *	2000-05-25	2001-11-29	Curagen Corporation	Method of detecting inflammatory lung disorders
WO2002000933A2 (en) *	2000-06-23	2002-01-03	Interleukin Genetics, Inc.	Screening assays for identifying modulators of the inflammatory or immune responses
US20040029129A1 (en) *	2001-10-25	2004-02-12	Liangsu Wang	Identification of essential genes in microorganisms
US20030170694A1 (en) *	2001-12-21	2003-09-11	Daniel Wall	Stabilized nucleic acids in gene and drug discovery and methods of use
WO2003099222A2 (en) *	2002-05-23	2003-12-04	Invitrogen Corporation	Pseudo-tissues and uses thereof
WO2004011496A2 (en)	2002-07-04	2004-02-05	Nalan Utku	Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
WO2004020666A2 (en) *	2002-09-02	2004-03-11	Evotec Neurosciences Gmbh	Diagnostic and therapeutic use of thyroid hormone binding protein for neurodegenerative diseases
US20050214292A1 (en) *	2002-10-18	2005-09-29	Wyeth	Compositions and methods for diagnosing and treating autoimmune disease
DE602004015064D1 (de) *	2003-01-06	2008-08-28	Wyeth Corp	Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
WO2004070062A2 (en) *	2003-02-04	2004-08-19	Wyeth	Compositions and methods for diagnosing and treating cancers
US20040191818A1 (en) *	2003-02-26	2004-09-30	O'toole Margot Mary	Compositions and methods for diagnosing and treating autoimmune diseases
JP2007537984A (ja) *	2003-03-04	2007-12-27	ワイス	喘息または他のアレルギー性もしくは炎症性疾患の診断および治療のための組成物および方法
EP1620564A4 (de) *	2003-04-18	2008-03-12	Cytovia Inc	Verfahren zur behandlung von auf apoptoseinduktion reagierenden krankheiten und screening-tests
US20050119210A1 (en) *	2003-05-20	2005-06-02	Xiaobing Be	Compositions and methods for diagnosing and treating cancers
WO2005020902A2 (en) *	2003-08-21	2005-03-10	Cytokine Pharmasciences, Inc.	Compositions and methods for treating and diagnosing irritable bowel syndrome
US20050164167A1 (en) *	2004-01-28	2005-07-28	Buscher Benjamin A.	Method of discovery and development of broad-spectrum antiviral drugs
EP3461813A1 (de) *	2004-05-23	2019-04-03	Gerard M. Housey	Theramuteinmodulatoren
US8431110B2 (en)	2005-05-23	2013-04-30	Hmi Medical Innovations, Llc.	Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
CN103789389B (zh)	2005-11-23	2017-01-04	杰勒德·M·豪斯	鉴定、合成、优化和表征蛋白调节剂的化合物和方法
EP1878744A1 (de) *	2006-07-13	2008-01-16	Max-Delbrück-Centrum für Molekulare Medizin (MDC)	Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren
US20090285819A1 (en) *	2006-11-15	2009-11-19	Functional Genetics, Inc.	Methods and compositions for treating influenza

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4480038A (en) *	1982-04-30	1984-10-30	E. I. Dupont De Nemours And Company	Density separation of protein overproducing bacteria
US4532204A (en) *	1982-07-19	1985-07-30	Massachusetts Institute Of Technology	Mutation assays involving blood cells that metabolize toxic substances
US5266464A (en) *	1988-02-10	1993-11-30	Ict Pharmaceuticals, Inc.	Method of screening for protein inhibitors and activators

1988
- 1988-02-10 US US07/154,206 patent/US4980281A/en not_active Expired - Lifetime
1989
- 1989-02-08 ES ES8900455A patent/ES2010131A6/es not_active Expired
- 1989-02-08 IE IE39889A patent/IE77332B1/en not_active IP Right Cessation
- 1989-02-09 EP EP89902686A patent/EP0403506B1/de not_active Revoked
- 1989-02-09 AU AU31840/89A patent/AU612948B2/en not_active Ceased
- 1989-02-09 WO PCT/US1989/000462 patent/WO1989007654A1/en not_active Ceased
- 1989-02-09 HU HU891433A patent/HU208555B/hu not_active IP Right Cessation
- 1989-02-09 RO RO145730A patent/RO118452B1/ro unknown
- 1989-02-09 IL IL8922789A patent/IL89227A/en not_active IP Right Cessation
- 1989-02-09 JP JP1502499A patent/JPH03503598A/ja active Pending
- 1989-02-09 DE DE68926816T patent/DE68926816T2/de not_active Expired - Fee Related
- 1989-02-09 CA CA000590540A patent/CA1334927C/en not_active Expired - Fee Related
- 1989-02-09 AT AT89902686T patent/ATE140267T1/de not_active IP Right Cessation
- 1989-02-10 MX MX014890A patent/MX165993B/es unknown
1990
- 1990-08-08 FI FI903918A patent/FI102618B1/fi not_active IP Right Cessation
- 1990-08-08 NO NO19903494A patent/NO313103B1/no not_active IP Right Cessation
- 1990-08-09 DK DK189590A patent/DK189590A/da not_active Application Discontinuation
- 1990-08-10 BG BG092673A patent/BG60325B2/bg unknown
2001
- 2001-05-08 DK DK200100720A patent/DK200100720A/da not_active Application Discontinuation
2002
- 2002-03-07 NO NO20021142A patent/NO20021142D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JPH03503598A (ja)	1991-08-15
CA1334927C (en)	1995-03-28
DE68926816T2 (de)	1997-01-09
US4980281A (en)	1990-12-25
FI903918A0 (fi)	1990-08-08
EP0403506B1 (de)	1996-07-10
IL89227A0 (en)	1989-09-10
FI102618B (fi)	1999-01-15
HU208555B (en)	1993-11-29
NO20021142L (no)	1990-10-01
NO20021142D0 (no)	2002-03-07
DK189590D0 (da)	1990-08-09
DK189590A (da)	1990-10-02
MX165993B (es)	1992-12-15
DE68926816D1 (de)	1996-08-14
NO903494L (no)	1990-10-01
AU612948B2 (en)	1991-07-18
WO1989007654A1 (en)	1989-08-24
EP0403506A4 (en)	1991-07-24
ES2010131A6 (es)	1989-10-16
AU3184089A (en)	1989-09-06
IE890398L (en)	1989-08-10
IE77332B1 (en)	1997-12-02
NO903494D0 (no)	1990-08-08
FI102618B1 (fi)	1999-01-15
DK200100720A (da)	2001-05-08
RO118452B1 (ro)	2003-05-30
HUT55447A (en)	1991-05-28
EP0403506A1 (de)	1990-12-27
IL89227A (en)	1995-05-26
BG60325B2 (bg)	1994-05-27
ATE140267T1 (de)	1996-07-15

Legal Events

Date	Code	Title	Description
2005-10-10	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO313103B1 (no)	2002-08-12	Fremgangsmåte for screening for proteininhibitorer og aktiveringsmidler, samt testceller og testkit
US5688655A (en)	1997-11-18	Method of screening for protein inhibitors and activators
US5266464A (en)	1993-11-30	Method of screening for protein inhibitors and activators
Housey et al.	1988	Overproduction of protein kinase C causesdisordered growth control in rat fibroblasts
Michaud et al.	1995	14-3-3 is not essential for Raf-1 function: identification of Raf-1 proteins that are biologically activated in a 14-3-3-and Ras-independent manner
Bosch et al.	1997	Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1
Lemonidis et al.	2017	Peptide array-based screening reveals a large number of proteins interacting with the ankyrin-repeat domain of the zDHHC17 S-acyltransferase
Heidecker et al.	2020	Role of raf and myc oncogenes in signal transduction
Mortier et al.	2001	The focal adhesion targeting sequence is the major inhibitory moiety of Fak-related non-kinase
Rodriguez-Escudero et al.	2009	Phosphatidylinositol 3-kinase-dependent activation of mammalian protein kinase B/Akt in Saccharomyces cerevisiae, an in vivo model for the functional study of Akt mutations
Palermo et al.	2008	Importance of a C-terminal conserved region of Chk1 for checkpoint function
CA2112748A1 (en)	1993-01-21	A protein kinase associated with dna repair activity
LaFevre-Bernt et al.	1998	Phosphorylation and activation of cGMP-dependent protein kinase by Src
US20050065081A1 (en)	2005-03-24	Tyrosine kinase inhibitors
Liu	1995	Snk: The first of a novel family of serum inducible kinases
Campbell	1997	Functional analysis of conserved sequence motifs in polyomavirus tumor antigens required for interactions with cellular proteins
Utama	2003	Characterization of OS-9, a novel Myc-interacting protein
Stacey	1997	Characterisation of MBF: A cell cycle regulated fission yeast transcription complex
Ignatoski	1995	Biochemical and biological analysis of the autophosphorylation requirement for kinase activity and transforming ability of proteins encoded by host-range V-SRC alleles
Hayne	2004	Regulation of the Raf-1/MEK/ERK signaling module in mitosis
Alexandropoulos	2000	Murine Models of Breast Cancer: Assessment of the Role of c-Src in Mammary Tumorigenesis
Bauer et al.	1997	A novel 39-kilodalton membrane protein binds GTP in polyomavirus-transformed cells
Ho	2000	The Activation of Mitogen-Activated Protein Kinase Pathways by the TEL-JAK2 Oncoprotein